464 related articles for article (PubMed ID: 25369992)
1. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
2. Denosumab treatment is associated with decreased cortical porosity and increased bone density and strength at the proximal humerus of ovariectomized cynomolgus monkeys.
Haider IT; Sawatsky A; Zhu Y; Page R; Kostenuik PJ; Boyd SK; Edwards WB
Bone; 2022 Nov; 164():116517. PubMed ID: 35961611
[TBL] [Abstract][Full Text] [Related]
3. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
[TBL] [Abstract][Full Text] [Related]
4. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody.
Kostenuik PJ; Smith SY; Jolette J; Schroeder J; Pyrah I; Ominsky MS
Bone; 2011 Aug; 49(2):151-61. PubMed ID: 21457806
[TBL] [Abstract][Full Text] [Related]
5. Twelve Months of Denosumab and/or Alendronate Is Associated With Improved Bone Fatigue Life, Microarchitecture, and Density in Ovariectomized Cynomolgus Monkeys.
Haider IT; Loundagin LL; Sawatsky A; Kostenuik PJ; Boyd SK; Edwards WB
J Bone Miner Res; 2023 Mar; 38(3):403-413. PubMed ID: 36533719
[TBL] [Abstract][Full Text] [Related]
6. Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab.
Ominsky MS; Libanati C; Niu QT; Boyce RW; Kostenuik PJ; Wagman RB; Baron R; Dempster DW
J Bone Miner Res; 2015 Jul; 30(7):1280-9. PubMed ID: 25684625
[TBL] [Abstract][Full Text] [Related]
7. Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling/modeling in newly ovariectomized monkeys.
Duong LT; Pickarski M; Cusick T; Chen CM; Zhuo Y; Scott K; Samadfam R; Smith SY; Pennypacker BL
Bone; 2016 Jul; 88():113-124. PubMed ID: 27126999
[TBL] [Abstract][Full Text] [Related]
8. Individual and combined effects of exercise and alendronate on bone mass and strength in ovariectomized rats.
Fuchs RK; Shea M; Durski SL; Winters-Stone KM; Widrick J; Snow CM
Bone; 2007 Aug; 41(2):290-6. PubMed ID: 17544352
[TBL] [Abstract][Full Text] [Related]
9. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
10. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
[TBL] [Abstract][Full Text] [Related]
11. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
[TBL] [Abstract][Full Text] [Related]
12. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
Pierroz DD; Bonnet N; Baldock PA; Ominsky MS; Stolina M; Kostenuik PJ; Ferrari SL
J Biol Chem; 2010 Sep; 285(36):28164-73. PubMed ID: 20558734
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.
Sakai S; Endo K; Takeda S; Mihara M; Shiraishi A
Bone; 2012 May; 50(5):1054-63. PubMed ID: 22366400
[TBL] [Abstract][Full Text] [Related]
14. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
Sugimoto M; Futaki N; Harada M; Kaku S
Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
[TBL] [Abstract][Full Text] [Related]
15. Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats.
Luo Y; Zhang L; Wang WY; Hu QF; Song HP; Su YL; Zhang YZ
Bone; 2013 Aug; 55(2):439-48. PubMed ID: 23500174
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.
Gerstenfeld LC; Sacks DJ; Pelis M; Mason ZD; Graves DT; Barrero M; Ominsky MS; Kostenuik PJ; Morgan EF; Einhorn TA
J Bone Miner Res; 2009 Feb; 24(2):196-208. PubMed ID: 19016594
[TBL] [Abstract][Full Text] [Related]
17. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
18. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
19. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.
Balena R; Toolan BC; Shea M; Markatos A; Myers ER; Lee SC; Opas EE; Seedor JG; Klein H; Frankenfield D
J Clin Invest; 1993 Dec; 92(6):2577-86. PubMed ID: 8254015
[TBL] [Abstract][Full Text] [Related]
20. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.
Williams DS; McCracken PJ; Purcell M; Pickarski M; Mathers PD; Savitz AT; Szumiloski J; Jayakar RY; Somayajula S; Krause S; Brown K; Winkelmann CT; Scott BB; Cook L; Motzel SL; Hargreaves R; Evelhoch JL; Cabal A; Dardzinski BJ; Hangartner TN; Duong LT
Bone; 2013 Oct; 56(2):489-96. PubMed ID: 23806798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
